TipRanks
Advertisement
Advertisement

AU:DXB Stock Latest News

Dimerix Wins ASX Waiver to Secure Related-Party Funding in A$50m Facility
Company AnnouncementsDimerix Wins ASX Waiver to Secure Related-Party Funding in A$50m Facility
1m ago
DXB
Dimerix to Showcase Kidney Disease Pipeline and Growth Strategy at E&P Healthcare Conference
PremiumCompany Announcements
Dimerix to Showcase Kidney Disease Pipeline and Growth Strategy at E&P Healthcare Conference
6d ago
DXB
Dimerix Highlights Kidney Disease Focus and Development Risks in Investor Update
PremiumCompany Announcements
Dimerix Highlights Kidney Disease Focus and Development Risks in Investor Update
15d ago
DXB
S&P Dow Jones Indices Unveils September 2026 Rebalance of S&P/ASX Benchmarks
PremiumCompany Announcements
S&P Dow Jones Indices Unveils September 2026 Rebalance of S&P/ASX Benchmarks
18d ago
DXB
Dimerix Seeks Trading Halt Ahead of Non-Dilutive Funding Update
PremiumCompany Announcements
Dimerix Seeks Trading Halt Ahead of Non-Dilutive Funding Update
20d ago
DXB
Dimerix Files 2026 Corporate Governance Disclosures with ASX
PremiumCompany AnnouncementsDimerix Files 2026 Corporate Governance Disclosures with ASX
26d ago
DXB
Dimerix lifts revenue but annual loss more than doubles
Premium
Company Announcements
Dimerix lifts revenue but annual loss more than doubles
26d ago
DXB
Dimerix Secures US$10m Everest Payment as DMX-200 Global Strategy Advances
Premium
Company Announcements
Dimerix Secures US$10m Everest Payment as DMX-200 Global Strategy Advances
1M ago
DXB
Dimerix Takes Control of U.S. IND for New Renal Asset DMX-652
PremiumCompany Announcements
Dimerix Takes Control of U.S. IND for New Renal Asset DMX-652
1M ago
DXB
Dimerix highlights kidney disease pipeline and diversification strategy at Bioshares Summit
PremiumCompany Announcements
Dimerix highlights kidney disease pipeline and diversification strategy at Bioshares Summit
2M ago
DXB
Dimerix to Highlight Kidney Disease Pipeline Progress at TechKnow Invest Conference
PremiumCompany Announcements
Dimerix to Highlight Kidney Disease Pipeline Progress at TechKnow Invest Conference
2M ago
DXB
Dimerix Secures Long-Term U.S. Patent Protection for Phase 2 Kidney Drug DMX-652
PremiumCompany Announcements
Dimerix Secures Long-Term U.S. Patent Protection for Phase 2 Kidney Drug DMX-652
2M ago
DXB
Dimerix Strikes Major Asian Licensing Deal for Phase 3 Kidney Drug DMX-200
PremiumCompany AnnouncementsDimerix Strikes Major Asian Licensing Deal for Phase 3 Kidney Drug DMX-200
3M ago
DXB
Dimerix Highlights ACTION3 Trial De-Risking and Commercial Potential for DMX-200
Premium
Company Announcements
Dimerix Highlights ACTION3 Trial De-Risking and Commercial Potential for DMX-200
5M ago
DXB
Dimerix Confirms Strong Statistical Power and Refines Strategy for Phase 3 FSGS Trial
Premium
Company Announcements
Dimerix Confirms Strong Statistical Power and Refines Strategy for Phase 3 FSGS Trial
5M ago
DXB
Dimerix to Court Singapore Investors With Update on Phase 3 Kidney Drug
PremiumCompany Announcements
Dimerix to Court Singapore Investors With Update on Phase 3 Kidney Drug
6M ago
DXB
Dimerix Over-Recruits in Pivotal FSGS Phase 3 Trial as Last Adult Patient Dosed
PremiumCompany Announcements
Dimerix Over-Recruits in Pivotal FSGS Phase 3 Trial as Last Adult Patient Dosed
7M ago
DXB
Dimerix Courts Investors With Perth and Singapore Briefings on FSGS Phase 3 Program
PremiumCompany Announcements
Dimerix Courts Investors With Perth and Singapore Briefings on FSGS Phase 3 Program
7M ago
DXB
Dimerix to Showcase Phase 3 FSGS Program at Oppenheimer Healthcare Conference
PremiumCompany Announcements
Dimerix to Showcase Phase 3 FSGS Program at Oppenheimer Healthcare Conference
7M ago
DXB
Dimerix Revenue Surges but Loss Deepens and Asset Base Thins
PremiumCompany AnnouncementsDimerix Revenue Surges but Loss Deepens and Asset Base Thins
7M ago
DXB
Dimerix to Showcase Phase 3 FSGS Program and Growth Strategy at Euroz Hartleys Healthcare Forum
Premium
Company Announcements
Dimerix to Showcase Phase 3 FSGS Program and Growth Strategy at Euroz Hartleys Healthcare Forum
8M ago
DXB
Dimerix Hits Phase 3 Recruitment Target for Lead Kidney Drug as FDA Backs Approval Pathway
Premium
Company Announcements
Dimerix Hits Phase 3 Recruitment Target for Lead Kidney Drug as FDA Backs Approval Pathway
8M ago
DXB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >